WEST CHESTER, Ohio, Oct. 22 AtriCure, Inc.(Nasdaq: ATRC), a medical device company focused on developing, manufacturingand selling innovative cardiac surgical devices, will release its financialresults for the quarter ended September 30, 2007 on Tuesday, November 6, 2007.
AtriCure will host a conference call at 10:00 am ET on Tuesday, November6, 2007 to discuss third quarter 2007 results. A live web cast of theconference call will be available online from the investor relations page ofAtriCure's corporate web site at www.atricure.com.
Pre-registration is available for this call at the following URL:https://www.theconferencingservice.com/prereg/key.process?key=PWTAHHJ3Q
Pre-registering is not mandatory but is recommended as it will provide youimmediate entry into the call and will facilitate the timely start of theconference. Pre-registration only takes a few moments and you may pre-registerat any time, including up to and after the call start time. Alternatively, ifyou prefer being placed into the call by an operator, please call(888) 713-4218 for domestic callers and (617) 213-4870 for internationalcallers at least 15 minutes prior to the call start time and use reservationnumber 91207687.
The web cast will remain available on AtriCure's web site through December6, 2007. A telephonic replay of the call will also be available untilDecember 6, 2007. The replay dial-in numbers are (888) 286-8010 for domesticcallers and (617) 801-6888 for international callers. Please use reservationcode 85213467.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company focused on developing,manufacturing and selling innovative cardiac surgical devices designed tocreate precise lesions, or scars, in cardiac, or heart, tissues. Medicaljournals have described the adoption by leading cardiothoracic surgeons of theAtriCure Isolator(R) bipolar ablation clamps as a treatment alternative duringopen-heart surgical procedures to create lesions in cardiac tissue to blockthe abnormal electrical impulses that cause atrial fibrillation, or AF, arapid, irregular quivering of the upper chambers of the heart. Additionally,leading cardiothoracic surgeons have described the AtriCure Isolator(R) clampsas a promising treatment alternative for patients who may be candidates forsole-therapy minimally invasive procedures. AF affects more than 2.5 millionAmericans and predisposes them to a five-fold increased risk of stroke.
The FDA has cleared the AtriCure Isolator(R) bipolar ablation system,including the new Isolator Synergy(TM) ablation clamps, for the ablation, ordestruction, of soft tissues in general and cardiac related surgicalprocedures, but to date has not cleared or approved the system for thetreatment of AF. The FDA has cleared the AtriCure multifunctional bipolar Penfor the ablation of cardiac tissue and for temporary pacing, sensing,stimulating and recording during the evaluation of cardiac arrhythmias, butthe multifunctional bipolar Pen has not been approved for the treatment of AF.Contact: AtriCure, Inc. Julie A. Piton Vice President and Chief Financial Officer (513) 755-4561 email@example.com
SOURCE AtriCure, Inc.